Bevacizumab and Erlotinib in the Treatment of Patients With Carcinoma of Unknown Primary Site

NCT00193622 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Neoplasms, Unknown Primary

Interventions

DRUG: Bevacizumab
DRUG: Erlotinib

Sponsor

SCRI Development Innovations, LLC

Collaborators

[object Object]